Form 4: Corcept Therapeutics Director Exercises Options and Sells Shares Under Pre-Arranged Plan
Insider Transaction Disclosure
A director at Corcept Therapeutics Inc. exercised stock options and simultaneously sold an equivalent number of common shares, as disclosed in a recent SEC Form 4 filing.
Summary
- Daniel N. Swisher Jr., a Director of Corcept Therapeutics Inc. (CORT), engaged in transactions involving the company's common stock on July 10, 2025.
- Swisher exercised stock options to acquire 2,200 shares of common stock at an exercise price of $14.08 per share.
- Concurrently, on the same date, Swisher sold 2,200 shares of common stock at a price of $71.08 per share.
- These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2024.
- Following these transactions, Swisher's direct beneficial ownership of common stock is 0 shares.
- Swisher's direct beneficial ownership of stock options is 7,700 shares, which are fully exercisable and expire on August 20, 2028.
Sentiment
Score: 6
Explanation: The transaction represents a pre-planned exercise of options and sale of shares by a director, indicating a realization of value by the insider. While it reduces direct share ownership, it was conducted under a 10b5-1 plan, which is a standard practice for insider liquidity.
Positives
- The sale was executed at a significantly higher price ($71.08) than the option exercise price ($14.08), indicating a substantial gain for the insider.
- The transaction was pre-planned under a Rule 10b5-1 plan, which suggests a structured approach to insider trading and can mitigate concerns about opportunistic timing.
Negatives
- The director's direct beneficial ownership of common stock in the company is now 0 shares, which could be interpreted as a reduction in direct equity alignment with shareholders, although options are still held.
Future Outlook
No future outlook or guidance is provided in this insider transaction disclosure.
Industry Context
This filing is a standard insider transaction disclosure and does not provide specific industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2024, which is a common corporate governance practice for insiders to manage their equity holdings. | 2024-08-01 | The use of a 10b5-1 plan demonstrates a pre-arranged and transparent approach to insider trading, reducing concerns about opportunistic timing of transactions. |
Stakeholder Impact
- Shareholders: May view the sale as an insider taking profits, but the pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The director still holds significant stock options, maintaining an equity interest.
Key Dates
| Date | Description |
|---|---|
| 2024-08-01 | Date Rule 10b5-1 plan was adopted by Daniel N. Swisher Jr. |
| 2025-07-10 | Date of stock option exercise and concurrent sale of common stock. |
| 2025-07-14 | Date the Form 4 was signed. |
| 2028-08-20 | Expiration date of the remaining stock options held by Daniel N. Swisher Jr. |
Keywords
Corcept Therapeutics, CORT, SEC Form 4, Insider Trading, Stock Options, Share Sale, Director, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.